Zika virus-specific synthetic molecule can differentiate between prior infections with different flaviviruses

FHS
May 14, 2024
12:47 pm

A newly discovered Zika virus-specific synthetic molecule is capable of differentiating Zika-immune patient samples from samples of patients previously infected with the related dengue virus.

UK’s NICE recommends AbbVie’s Aquipta to treat migraines – Pharmaceutical Technology

Share this article According to GlobalData, the migraine drugs market is set to be worth $18.6bn in 2030 globally. Credit: Krakenimages.com via Shutterstock. The National

April 11, 2024

Data Insights – Pharmaceutical Technology

By Company Name No Filter Selected Bristol-Myers Squibb (439) Novartis (279) Merck (277) AstraZeneca (232) Pfizer (226) F. Hoffmann-La Roche (204) AbbVie (179) BeiGene (151)

January 23, 2024

Toripalimab by Shanghai Junshi Biosciences for Gallbladder Cancer: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

November 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.